Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/bmt.2008.12 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rituximab therapy in severe connective tissue disease associated interstitial lung disease: A retrospective single-centre observational study.
Afr J Thorac Crit Care Med
October 2024
Wits Donald Gordon Medical Centre, University of the Witwatersrand, Johannesburg, South Africa.
Background: Connective tissue disease-associated interstitial lung disease (CTD-ILD) that progresses despite first-line immunosuppressive therapy is a clinical challenge. Rituximab (RTX) is a chimeric monoclonal antibody targeted to CD20+ B cells, resulting in B-cell depletion, and has been used as a salvage therapeutic modality in severe disease.
Objectives: To investigate the therapeutic effects and safety of RTX in patients with severe CTD-ILD.
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.
Br J Haematol
November 2024
AOU Città della Salute e della Scienza di Torino-Ematologia U, Turin, Italy.
This multicentre phase II study Fondazione Italiana Linfomi (FIL)-bortezomib plus rituximab plus bendamustine (BRB) tested a combination of bendamustine (90 mg/m on days 1-2), rituximab (375 mg/m intravenously on day 1) and bortezomib (1.3 mg/m sc on days 1, 8, 15, 22) every 28 days for six cycles in 38 symptomatic patients with relapsed/refractory Waldenstrom macroglobulinaemia (RR-WM). Moreover, MYD88 and CXCR4 mutations were tested by droplet digital polymerase chain reaction (ddPCR) both at baseline and at the end of treatment in 21 patients.
View Article and Find Full Text PDFTreatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium.
Blood Adv
November 2024
University of Rochester Medical Center, Rochester, New York, United States.
Article Synopsis
- Progression of disease within 24 months of initial immunochemotherapy (POD24) in follicular lymphoma (FL) is linked to worse patient outcomes, and there is currently no standard treatment for these patients.
- A study of 256 FL patients with POD24 revealed diverse treatment approaches, with bendamustine-rituximab patients mostly receiving R-CHOP therapy and R-CHOP patients opting for aggressive salvage therapy.
- The overall response rate to treatments after POD24 was 66%, with a complete response rate of 40%, while factors like age over 70 and high-risk FLIPI scores worsened overall survival outcomes (73% at 5 years).
Advances in Primary Central Nervous System Lymphoma.
Curr Neurol Neurosci Rep
November 2024
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, 875 Blake Wilbur, MC 6510, Stanford, Palo Alto, CA, 94305, USA.
Article Synopsis
- This article reviews the importance of optimal initial management in primary CNS lymphoma (PCNSL) and its potential impact on long-term patient outcomes.
- Recent advances include using genomic analysis of CSF cell-free DNA for diagnosis and improved treatment options for younger patients, where chemotherapy has shown high cure rates.
- In contrast, older patients still face poor outcomes, prompting investigations into new therapies and consolidation options like low-dose radiation, while ongoing clinical trials aim to address their treatment needs.
Plerixafor in association with R-DHAP and G-CSF to mobilize a large number of CD34 + cells in patients with relapsed-refractory diffuse large B-cell lymphomas.
Ann Hematol
December 2024
Hematology and Transplant Unit, "Cardinal Panico" Hospital, Tricase, LE, Italy.
Lymphoma and plasma cell disorders are the most common indications for autologous hematopoietic stem cell (HSC) transplantation. We conducted a prospective multicenter study with the aim of testing the feasibility of plerixafor (PLX) in combination with R-DHAP and G-CSF in 37 patients with relapsed refractory diffuse large B-cell lymphoma (R/R DLBCL) in order to collect a large number of HSC with a goal of transplantation. After R-DHAP, daily monitoring of peripheral blood CD34 + cells by flow cytometry was performed starting on day + 13.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!